Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 20/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29829804 | 1.00 | AKR1B1 (0.82) | AKR1B1 | |
| SCHEMBL15217606 | 0.87 | AKR1B1 (0.82) | AKR1B1 | |
| SCHEMBL19747022 | 0.86 | AKR1B1 (0.80) | AKR1B1 | |
| SCHEMBL26379326 | 0.86 | AKR1B1 (0.80) | AKR1B1 | |
| SCHEMBL19747448 | 0.86 | AKR1B1 (0.80) | AKR1B1 | |
| SCHEMBL19747171 | 0.85 | AKR1B1 (0.61) | AKR1B1 | |
| SCHEMBL26700470 | 0.84 | AKR1B1 (0.58) | AKR1B1 | |
| Govorestat SCHEMBL31081639 | 0.83 | AKR1B1 (0.81) | AKR1B1 | |
| Govorestat SCHEMBL19747408 | 0.83 | AKR1B1 (0.81) | AKR1B1 | |
| SCHEMBL9321650 | 0.82 | AKR1B1 (1.00) | AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163073-A1 | ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2025-05-22 | — | — | US | disclosed |
| US-12077547-B2 | Aldose reductase inhibitors and methods of use thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-09-03 | — | — | US | disclosed |
| US-20240238288-A1 | ALDOSE REDUCTASE INHIBITORS FOR TREATING SORBITOL DEHYDROGENASE DEFICIENCY | BARCLAYS BANK PLC (GB) | 2024-07-18 | — | — | US | disclosed |
| US-20240238288-A1 | ALDOSE REDUCTASE INHIBITORS FOR TREATING SORBITOL DEHYDROGENASE DEFICIENCY | BARCLAYS BANK PLC (GB) | 2024-07-18 | — | — | US | disclosed |
| CN-115160339-B | Aldose reductase inhibitors and methods of use thereof | 纽约市哥伦比亚大学理事会 | 2024-05-14 | — | — | CN | disclosed |
| EP-4316603-A2 | 4-OXO-3,4-DIHYDROTHIENO[3,4-D]PYRIDAZINE COMPOUNDS AS ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF | The Trustees of Columbia University in the City of New York (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20240033263-A1 | COMBINATION OF ALDOSE REDUCTASE INHIBITORS AND PROBENECID FOR THE TREATMENT OF DIABETIC COMPLICATIONS | MYLARI Banavara (US) | 2024-02-01 | — | — | US | disclosed |
| US-20230346782-A1 | COMPOSITIONS AND METHODS FOR TREATING GALACTOSEMIA | BARCLAYS BANK PLC (GB) | 2023-11-02 | — | — | US | disclosed |
| US-20230346782-A1 | COMPOSITIONS AND METHODS FOR TREATING GALACTOSEMIA | BARCLAYS BANK PLC (GB) | 2023-11-02 | — | — | US | disclosed |
| EP-3757107-B1 | 4-OXO-3,4-DIHYDROTHIENO[3,4-D]PYRIDAZINE COMPOUNDS AS ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF | UNIV COLUMBIA (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20200230139-A1 | COMPOSITIONS AND METHODS FOR TREATING GALACTOSEMIA | BARCLAYS BANK PLC (GB) | 2020-07-23 | — | — | US | disclosed |
| US-10647726-B2 | Aldose reductase inhibitors and methods of use thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-05-12 | — | — | US | disclosed |
| US-10647726-B2 | Aldose reductase inhibitors and methods of use thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190300543-A1 | ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2019-10-03 | — | — | US | disclosed |
| US-20190300543-A1 | ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2019-10-03 | — | — | US | disclosed |
| WO-2019023648-A1 | COMPOSITIONS AND METHODS FOR TREATING GALACTOSEMIA | APPLIED THERAPEUTICS INC. (US) | 2019-01-31 | — | — | WO | disclosed |
| US-10150779-B2 | Aldose reductase inhibitors and methods of use thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2018-12-11 | — | — | US | disclosed |
| US-20180237451-A1 | ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2018-08-23 | — | — | US | disclosed |
| EP-3352754-A1 | ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF | The Trustees of Columbia University in the City of New York (US) | 2018-08-01 | — | — | EP | disclosed |
| WO-2017223179-A1 | ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163073-A1 | ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF | ALDOA, AKR1B1, AKR1C2 | AKR1B1 2/4885 |
| US-20200230139-A1 | COMPOSITIONS AND METHODS FOR TREATING GALACTOSEMIA | GLA, ALDOA, GALC | AKR1B1 42/4885 |
| US-20240238288-A1 | ALDOSE REDUCTASE INHIBITORS FOR TREATING SORBITOL DEHYDROGENASE DEFICIENCY | SORD, SDHA, SDHB | AKR1B1 9/4885 |
| US-20240033263-A1 | COMBINATION OF ALDOSE REDUCTASE INHIBITORS AND PROBENECID FOR THE TREATMENT OF DIABETIC COMPLICATIONS | AKR1C2, AKR1C1, AKR1C4 | AKR1B1 6/4885 |
| US-20230346782-A1 | COMPOSITIONS AND METHODS FOR TREATING GALACTOSEMIA | GLA, ALDOA, GALC | AKR1B1 42/4885 |
| US-20180237451-A1 | ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF | ALDOA, AKR1B1, AKR1C2 | AKR1B1 2/4885 |
| US-20190300543-A1 | ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF | ALDOA, AKR1B1, AKR1C2 | AKR1B1 2/4885 |
| US-10150779-B2 | Aldose reductase inhibitors and methods of use thereof | ALDOA, AKR1B1, AKR1C2 | AKR1B1 2/4885 |
| US-10647726-B2 | Aldose reductase inhibitors and methods of use thereof | ALDOA, AKR1B1, AKR1C2 | AKR1B1 2/4885 |
| US-12077547-B2 | Aldose reductase inhibitors and methods of use thereof | ALDOA, AKR1B1, AKR1C2 | AKR1B1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.